0001737287-23-000025.txt : 20230316
0001737287-23-000025.hdr.sgml : 20230316
20230316173226
ACCESSION NUMBER: 0001737287-23-000025
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230314
FILED AS OF DATE: 20230316
DATE AS OF CHANGE: 20230316
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chang David D
CENTRAL INDEX KEY: 0001611024
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38693
FILM NUMBER: 23739958
MAIL ADDRESS:
STREET 1: C/O ALLOGENE THERAPEUTICS, INC.
STREET 2: 210 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Allogene Therapeutics, Inc.
CENTRAL INDEX KEY: 0001737287
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 823562771
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 210 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 457-2700
MAIL ADDRESS:
STREET 1: 210 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2023-03-14
0
0001737287
Allogene Therapeutics, Inc.
ALLO
0001611024
Chang David D
C/O ALLOGENE THERAPEUTICS, INC.
210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
President and CEO
Common Stock
2023-03-14
4
F
0
22340
5.56
D
2269447
D
Common Stock
1201108
I
See footnote
Common Stock
856044
I
See footnote
Common Stock
856044
I
See footnote
Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.49 to $5.595, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Includes 135 and 2000 share of the Issuer's common stock acquired by the reporting person on September 15, 2021 and on March 15, 2023 pursuant to an employee stock purchase program, respectively.
Securities held in the name of the Chang 2006 Family Trust
Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
Securities held in the name of the RTC 2019 Trust dated October 1, 2019.
Veer Bhavnagri as attorney-in-fact
2023-03-16